Investor Center

  1. Stock Information

  2. Financial Reports

  3. Conferences & Events

  4. Press Releases

  5. Financial Calendar

  6. Annual General Meeting

  7. Corporate Governance

  8. IR-Contact

Pentixapharm AG, a former subsidiary of Eckert & Ziegler Group, has successfully completed its spin-off into Pentixapharm Holding AG, followed by its listing on October 3, 2024, in the Prime Standard of the Frankfurt Stock Exchange. This page provides investors with key information about the company's recent IPO and the opportunities it offers in the radiopharmaceutical sector.

Prospectus for Public Offering – Dated September 23, 2024

Corporate Presentation

Investment Highlights

  • Business model focused on innovative radiopharmaceuticals for the diagnosis and therapy of various indications (theranostics)

  • Institutional environment characterized by high market growth and intense M&A activity

  • IPO as a strategic step to secure short- and long-term financing

  • Lead candidate PentixaFor already in Phase III

  • Commercial rights to over 20 investigator-initiated studies (IIS) for accelerated pipeline development